JLL Partners poised for 60-plus-pct IRR on Patheon exit


JLL Partners, Patheon NV, Thermo Fisher Scientific, healthcare, private equity, merger, M&A
  • JLL acquired 51 pct stake in Patheon in 2014
  • Most of firm’s equity came from Fund VI
  • Deal values Patheon at $3.8 bln
JLL Partners stands to make 4x to 5x its investment in Patheon NV, according to a source with knowledge of the deal. Thermo Fisher Scientific is expected to close its acquisition of the drug-manufacturing business in the next three to five ...DON'T MISS IT! Now in its 10th year, PartnerConnect Midwest is bringing you 300 attendees, over 400 private ExecConnect meetings between LPs and GPs, and three insightful tracks including Buyouts Funds, Buyouts Deals and Co-Investments. REGISTER TODAY!

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition

BO_052917_cover

To read a digital copy of our latest magazine

click here

PE News Briefs